Trial intelligence / Profile preview

BREEZE-AD-PEDS: Baricitinib in Pediatric Atopic Dermatitis

2023-503898-38-00Phase 3Completed

Sponsor: Eli Lilly and Company
Start: Apr 2024
Modality: Small Molecules, Recombinant Proteins and Enzymes, Antibody-Based Therapeutics
Countries: 18

Overview

Phase 3, randomised, double-blind trial in atopic dermatitis (AD) comparing Baricitinib with Placebo (2 arms). Primary endpoints: Investigator's Global Assessment (IGA) Response, Cmax,ss of LY3009104 and 1 more. Started Apr 2024; status: completed.

Drugs

baricitinib

Conditions

atopic dermatitis (AD)

Beyond the preview

Go deeper on 2023-503898-38-00.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on 2023-503898-38-00.